Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2009

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

R-(-)-gossypol acetic acid

DRUG

temozolomide

GENETIC

gene expression analysis

GENETIC

mutation analysis

GENETIC

protein expression analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

adjuvant therapy

RADIATION

radiation therapy

Trial Locations (8)

30322

Winship Cancer Institute of Emory University, Atlanta

35294

Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48202

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00390403 - Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter